KALA BIO, Inc.
NASDAQ Global SelectCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Avi Minkowitz
- Full Time Employees
- 6
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 1167 Massachusetts Avenue Arlington MA United States of America 02476
- IPO Date
- Jul 20, 2017
- CIK
- 0001479419
- Website
- kalarx.com
- Similar Companies
- Business
- KALA BIO, Inc. (NASDAQ:KALA) is a clinical-stage biopharmaceutical company focused on the research, development, and commercialization of innovative biologics-based therapies for rare and severe diseases of the eye. The company utilizes its proprietary mesenchymal stem cell secretome (MSC-S) platform to develop product candidates that provide regenerative healing effects for ocular surface and retinal diseases; its lead product candidate, KPI-012, is a topically administered human MSC-S containing numerous biofactors including growth factors, protease inhibitors, matrix proteins, and neurotrophic factors, currently in Phase 2b clinical development for persistent corneal epithelial defect (PCED) with FDA orphan drug and fast track designations, and under evaluation for additional indications such as limbal stem cell deficiency (LSCD) and other rare corneal diseases; its preclinical candidate, KPI-014, targets rare inherited retinal diseases (IRDs) including retinitis pigmentosa and Stargardt disease via intravitreal administration to slow retinal degeneration in a gene-agnostic manner. KALA BIO, formerly known as Kala Pharmaceuticals, Inc., changed its name in August 2023 to reflect its sharpened focus on the MSC-S platform following the July 2022 sale of its previously approved commercial ophthalmic products, EYSUVIS and INVELTYS, to Alcon Inc.; most recently, in December 2025, the company entered into a $6 million securities purchase agreement with investor David E. Lazar, who was appointed CEO and Chairman to lead capital restructuring, product candidate redevelopment, and exploration of strategic alternatives after the Phase 2b CHASE trial of KPI-012 missed its primary endpoint in September 2025; earlier in 2025, KALA BIO completed a $10.75 million private placement and a $1.8 million preferred stock offering to support operations. Founded in 2009 and headquartered in Arlington, Massachusetts, with additional facilities in Menlo Park, California, KALA BIO targets underserved patient populations in the ophthalmology sector across the United States and Latin America through its clinical programs.
Company News
KALA Bio Signs Non-Binding LOI to Acquire Nationwide Telehealth Platform with Approximately $48 Million in Sales Since Inception
Kala Bio and Virotek Sign Letter of Intent with U.S. DNA Testing Platform to Resell Virotek's Suite of Genetic Testing Products
KALA BIO, Inc. (NASDAQ:KALA) Given Consensus Recommendation of “Reduce” by Brokerages
KALA BIO Adds Healthcare Operator Yenvy Truong to Advisory Team
Kala Bio and Virotek Finalize Definitive Agreement Establishing Exclusive U.S. Distribution Partnership for Ophthalmology Genetic Testing Program
Kala Bio and Virotek Announce Letter of Intent to Establish an Exclusive U.S. Distribution Partnership for Ophthalmology Genetic Testing Program
KALA BIO (KALA) Expected to Post Earnings on Thursday
KALA BIO Announces Reverse Stock Split
Kala Bio Celebrates Trump Executive Order as Game-Changer for Psychedelic Medicine
KALA BIO (NASDAQ:KALA) vs. Celularity (NASDAQ:CELU) Financial Survey
Kala Bio Engages Dr. Saeid Babaei as Senior Scientific Advisor to Evaluate Clinical Assets and Precision Development Opportunities
KALA BIO Delivers Industry-Leading AI Infrastructure: Bionic Intelligence Research Agent Now Live
EXCLUSIVE: Penny Stock Kala Bio Transitions To Revenue Model With AI Platform Launch
KALA BIO, Inc. (NASDAQ:KALA) Receives Consensus Rating of “Hold” from Analysts
Red Light Holland Engages Kala Bio's Researgency.AI Platform to Support Clinical Development of Filament's Patented PEX010 Botanical Psilocybin Drug Candidate
Red Light Holland Engages Kala Bio's Researgency.ai Platform to Support Clinical Development of Filament Health's Patented PEX010 Botanical Psilocybin Drug Candidate
Younet.ai Highlights Researgency.ai Collaboration with Kala Bio (KALA) as New "AutoResearch" Milestone Signals the Rise of Autonomous Research Agents
Kala Bio Launches a Revolution for Biotech- First AI Agent Deploying in 14 Days as $180 Billion Agentic AI Healthcare Revolution Accelerates
Stock Trend Capital Provides Younet AI Investment Update
KALA BIO Eyes Pharma R&D Spend With Secure AI Licensing Model